LivaNova (NASDAQ:LIVN) Sets New 12-Month High – Here’s What Happened

LivaNova PLC (NASDAQ:LIVN)’s share price hit a new 52-week high on Wednesday . The company traded as high as $58.91 and last traded at $58.72, with a volume of 388480 shares changing hands. The stock had previously closed at $58.32.

Wall Street Analyst Weigh In

A number of research analysts have recently weighed in on LIVN shares. Barclays raised their price objective on LivaNova from $55.00 to $58.00 and gave the company an “equal weight” rating in a research report on Thursday, August 21st. Needham & Company LLC reaffirmed a “buy” rating and issued a $64.00 price objective on shares of LivaNova in a research note on Wednesday, September 3rd. Wolfe Research raised LivaNova from a “peer perform” rating to an “outperform” rating and set a $60.00 price objective on the stock in a research note on Tuesday, May 20th. Finally, Wall Street Zen raised LivaNova from a “buy” rating to a “strong-buy” rating in a research note on Saturday, August 9th. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and one has given a Hold rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus price target of $59.71.

LivaNova Price Performance

The firm’s 50-day moving average price is $49.20 and its 200-day moving average price is $43.80. The company has a current ratio of 1.29, a quick ratio of 1.09 and a debt-to-equity ratio of 0.31. The stock has a market capitalization of $3.21 billion, a PE ratio of -15.10 and a beta of 0.96.

LivaNova (NASDAQ:LIVN) last released its quarterly earnings results on Wednesday, August 6th. The company reported $1.05 EPS for the quarter, topping analysts’ consensus estimates of $0.84 by $0.21. LivaNova had a negative net margin of 16.13% and a positive return on equity of 14.57%. The firm had revenue of $352.50 million during the quarter, compared to analysts’ expectations of $332.20 million. During the same period in the previous year, the company earned $0.93 EPS. The firm’s revenue for the quarter was up 10.6% compared to the same quarter last year. On average, equities analysts forecast that LivaNova PLC will post 2.85 EPS for the current fiscal year.

Hedge Funds Weigh In On LivaNova

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. GAMMA Investing LLC raised its stake in LivaNova by 2,299.7% in the first quarter. GAMMA Investing LLC now owns 8,759 shares of the company’s stock valued at $344,000 after buying an additional 8,394 shares during the last quarter. Two Sigma Advisers LP raised its stake in LivaNova by 148.5% in the fourth quarter. Two Sigma Advisers LP now owns 214,545 shares of the company’s stock valued at $9,936,000 after buying an additional 128,200 shares during the last quarter. CWM LLC raised its stake in LivaNova by 52.3% in the first quarter. CWM LLC now owns 871 shares of the company’s stock valued at $34,000 after buying an additional 299 shares during the last quarter. Hsbc Holdings PLC raised its stake in LivaNova by 13.4% in the first quarter. Hsbc Holdings PLC now owns 6,666 shares of the company’s stock valued at $258,000 after buying an additional 790 shares during the last quarter. Finally, New York State Common Retirement Fund raised its stake in LivaNova by 28.6% in the first quarter. New York State Common Retirement Fund now owns 48,290 shares of the company’s stock valued at $1,897,000 after buying an additional 10,733 shares during the last quarter. Hedge funds and other institutional investors own 97.64% of the company’s stock.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.